"Non-invasive quantification of the genome and the epigenome.”
HPV TR-DNA For Cervical Cancer Screening
The current recommendation for women over 30 years old with normal cytology and a negative HPV DNA test is that the next screening testing be performed in three years. Our panel of TrDNA tests quantify high risk HPV, HPV DNA methylation and neoplastic cell DNA methylation. This panel can be used for cervical cancer screening and prevention.
We are the first to show that high risk HPV TrDNA can be quantified with qPCR and Sequence-Capture assays and that high-risk HPV genomes can be assembled from TrDNA.
We have developed qPCR and Sequence-Capture, Next-Generation Sequencing-based, HPV-Trans Renal DNA (TrDNA) assays to quantify high risk HPV DNA, which can be useful for cervical cancer screening.
Our HPV TrDNA assay compares favorably in Specificity and Sensitivity to commercial HPV tests, making them an ideal alternative for low resource settings.
LifeGene Biomarks, Inc
1612 Avenida Ponce de León
San Juan, PR 00909
Rafael Guerrero Preston, DrPH
Chief Scientific Officer
1550 Orleans Street
CRB2, Room 5M
Baltimore, MD 21231